読み込み中
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
前日終値
$25.27
−$0.64 · -2.47%
日中の時刻はETです。市場データは遅延する場合があります。
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
日中レンジ
現在 $25.27
52週レンジ
現在 $25.27
日中の時刻はETです。市場データは遅延する場合があります。
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
日中レンジ
現在 $25.27
52週レンジ
現在 $25.27
| 指標（USD） | 2025年度 |
|---|---|
| 売上高 | 7421.1万 USD |
| 売上原価 | 3250.6万 USD |
| 粗利益 | 4170.5万 USD |
| 研究開発 | 3747.1万 USD |
| 販売・一般管理 | 3556.8万 USD |
| 営業費用 | 7303.9万 USD |
| 受取利息 | 216万 USD |
| 支払利息 | 40.1万 USD |
| 減価償却費と償却費 | 386.4万 USD |
| 営業利益 | −3133.4万 USD |
| 純利益 | −2981.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$33.50
上昇余地（32.57%）この株式へのエクスポージャーを報告している上場投資信託です。
ARK Genomic Revolution ETFARKG2550.73万1.24%15.57億 USD0.75%$51.30+4.08%
Vanguard Morningstar Total Stock Market ETFVTI978.07万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM909.02万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF418.59万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO233万0.01%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO221.93万0.02%139.17億 USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA163.87万0.01%218.24億 USD0.03%$32.79+0.40%
Vanguard Russell 2000 Growth ETFVTWG30.34万0.02%17億 USD0.06%$260.49+0.91%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 Growth ETFVTWGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
